Previous 10 | Next 10 |
home / stock / argnf / argnf news
2024-01-14 10:25:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy outperfor...
2024-01-13 12:05:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International growth e...
2024-01-10 11:15:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. International growth e...
Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART ® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024 Reported positive data from Phase 2 ARDA study establis...
Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 42 nd Annual J....
2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...
ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indication Update on BALLAD study GO/NO GO decision Conference call scheduled for today, December 20, 2023, at 8:30am ET (2:30pm CET) Regulated Information – ...
2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...
Study did not meet primary or secondary endpoints Favorable safety and tolerability profile consistent with previous clinical trials Conference call scheduled for today, November 28, 2023 at 8:30am ET (2:30pm CET) Regulated information – Inside information ...
2023-11-27 11:04:09 ET Summary argenx's Q3 earnings exceeded expectations, with Vyvgart sales beating by 11%, indicating strong market demand. The anticipated approval for Vyvgart in CIDP by H2 2024 suggests continued positive sales growth. argenx's robust cash position, incre...
News, Short Squeeze, Breakout and More Instantly...
Argen X NV Company Name:
ARGNF Stock Symbol:
OTCMKTS Market:
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP) First novel, precision mechanism of action in more than 30 years for patients with CIDP Third approved indication for VYVGART®...
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline candidates to be introduced highlighting long-term commi...